A popular weight-loss drug is among those being reviewed in the UK after being linked to reports of suicidal or self-harming thoughts within patients.
Reuters reports that the Medicines and Healthcare Products Regulatory Agency (MHRA) said in the statement that it was reviewing a class of drugs known as GLP-1 receptor agonists, sold by the company Novo Nordisk.